Aarti Industries Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/6zqk7u5eszn5qt5u6yy18yzb.pdf

Key Takeaways


The Inventory Destocking Cycle

Rajendra Gogri: "Structurally, the chemicals are required by the end user, whether it is pharma, agro, or for paint or car or all the end users, there is no change. There are no new chemicals which have come in."

Segment-Level Pain Points

SegmentTrendCommentary
PDA (domestic dyes, export polymers)▼ Worst hitPolymer-side correction started more recently, causing a sharp decline; domestic dye demand remains weak.
Textiles▼ Prolonged weaknessStarted getting impacted in FY23 and still not showing any significant increase.
Pigments▬ Bottoming outSome green shoots possible from Q2 onwards; appears to have reached a floor.
Polymers & additives▼ Late-cycle correctionCorrections started more recently; may bottom out only toward Q3–Q4.
Nitrotoluene▲ Strong Q1, then ▼Strong Q1 volumes driven by agro demand, but Q2 and Q3 will see subdued numbers due to inventory correction.
Pharma (30% of domestic)▬ StableNo change in demand; China has been aggressive in exporting to India in this segment.

Long-Term Contracts: Asymmetric Exposure

Rajendra Gogri: "It's a very specialized plant; it's a continuous plant and difficult to use for other products. But we will take a call on that, maybe in the next 1 or 2 quarters, on whether we can really make a substantial modification in that facility and introduce new products because we have 2 different lines there; maybe 1 line we can repurpose or so."

Margin & Profitability Mechanics


Capex, Balance Sheet & Liquidity


Demand Recovery: The H2 Bet

Rajendra Gogri: "A lot of customers have given guidance and an indication on the kind of material they will need from October to March. We have received this for a lot of customers who were not buying. Some of them were not buying for 3 months also."

Guidance & Commitments

CommitmentSpecificsTimeline
Volume recoveryGradual recovery, weighted to Q3 and Q4 over Q2H2 FY24
Inventory correction completionDestocking settles; new inventory normal establishedEnd of calendar year 2023
Q2 EBITDASimilar range to Q1 (~₹200 crore)Q2 FY24
Dicamba plant decisionCall on substantial modification and product repurposingNext 1–2 quarters
Chlorotoluene commissioningFirst phase (~₹1,500 crore capex) on streamFY26 (some possibly FY27)
Nitrotoluene & ethylation block commissioningNew capacity operationalQ1 FY25
Tax rateSub-10%FY24
Debt-to-equity0.56–0.6x target; 0.7x worst caseOngoing
Annual debt repayment~₹350 crore, managed from current cash flowsOngoing
FY25 EBITDA (previous ₹1,700 crore guidance)Decline of 5–10% or a little more possible; clarity in next couple of quartersFY25

Key Metrics

MetricQ1 FY24
Revenue₹1,571 cr, declined 10% YoY
EBITDA₹201 cr, down 29% YoY
EBITDA margin14%
Profit after tax₹70 cr
CAPEX during the quarterover ₹260 cr
Expected CAPEX over next two years₹2,500–3,000 cr
Net debt~₹2,650 cr; gross debt ~₹3,000 cr, cash surplus ~₹400 cr
Net debt-to-equity0.56; peak target 0.6–0.7, worst-case outer limit 0.7
Direct export share45% to 50%; indirect export 20% to 25%, 70% of business linked to international market
Nitrochlorobenzene production17,293 MT, vs 20,515 MT in Q1 FY23
Nitro-Toluene production9,327 MT, vs 5,252 MT in Q1 FY23
Hydrogenation production2,868 TPM, vs 3,295 TPM in Q1 FY23
PDA production135 tonnes per month, vs 371 tonnes per month in Q1 FY23
NCB capacity expansioncompleted, from 75,000 TPA to 108,000 TPA
Annual debt repayment~₹350 cr
IFC long-tenure funding secured$130 million for new CAPEX initiatives